Loading clinical trials...
Loading clinical trials...
A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Conditions
Interventions
SPR001
Locations
8
United States
Spruce Biosciences Clinical Site
Orange, California, United States
Spruce Biosciences Clinical Site
San Diego, California, United States
Spruce Biosciences Clinical Site
Atlanta, Georgia, United States
Spruce Biosciences Clinical Site
Indianapolis, Indiana, United States
Spruce Biosciences Clinical Site
Ann Arbor, Michigan, United States
Spruce Biosciences Clinical Site
Minneapolis, Minnesota, United States
Start Date
September 6, 2018
Primary Completion Date
July 8, 2019
Completion Date
August 9, 2019
Last Updated
April 1, 2025
NCT06573723
NCT06712823
NCT03760835
NCT04463316
NCT07536269
NCT06900153
Lead Sponsor
Spruce Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions